Author | David Hutton

Articles

Company seeks first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications

July 08, 2020

Article

Patient enrollment for the NORSE 2 clinical trial has been completed, with safety and efficacy data expected to be reported in the third quarter of 2021.